BIOVITRUM AB
BiotechBIOVITRUM AB is a biotechnology company focused on Immunology.
BIOVITRUM AB's Key Drugs
BIOVITRUM AB's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
BIOVITRUM AB's Recent FDA Approvals
New NDA/BLA approvals for BIOVITRUM AB over the last two years — novel drugs only, excluding generics and label supplements.
BIOVITRUM AB's Therapeutic Areas
BIOVITRUM AB's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 2 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BIOVITRUM AB's Top Competitors
BIOVITRUM AB's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BIOVITRUM AB Pipeline Snapshot
Active clinical trials for BIOVITRUM AB across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2001-11-14
- Latest
- 2025-10-27
- Applications
- 2